002022 Shanghai Kehua Bio-engineering
- 7.57
- +0.01+0.13%
Shanghai Kehua Bio-engineering News
Kehua Biology (002022.SZ): Currently no genetic sequencing products
Gelonghui, May 9 | Kehua Biotech (002022.SZ) said on the investor interactive platform that the company currently has no genetic sequencing products and will continue to monitor the development of this technology field.
Kehua Biotech (002022.SZ) has spent 72.613,900 yuan to buy back 1.74% of shares
Kehua Biotech (002022.SZ) issued an announcement. As of April 30, 2024, the company has approved a total of shares...
Kehua Biotech (002022.SZ) reported first-quarter results with a net loss of RMB 28.8215 million
Kehua Biotech (002022.SZ) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
Shanghai Kehua Bio-EngineeringLtd (SZSE:002022 Investor Three-year Losses Grow to 58% as the Stock Sheds CN¥381m This Past Week
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But the long term shareholders of Shanghai Kehua Bio-Engineering Co.,Ltd (SZSE:00202
Kehua Biotech (002022.SZ): 2 products obtained medical device registration certificates
Gelonghui, April 12, 丨 Kehua Biotech (002022.SZ) announced that recently, Shanghai Kehua Bioengineering Co., Ltd. received the “Medical Device Registration Certificate” (in vitro diagnostic reagent) issued by the State Drug Administration. They are hepatitis E virus IgM antibody test kit (chemiluminescence method) and hepatitis B virus core IgM antibody test kit (chemiluminescence method), respectively.
Kehua Biotech (002022.SZ): The company has no hemorrhoid and laxative testing related products
Gelonghui, April 3 | Kehua Biotech (002022.SZ) said on the investor interactive platform that the company has no products related to hemorrhoid and laxative testing.
Kehua Biotech (002022.SZ): 1.67% of shares have been repurchased cumulatively
Gelonghui, April 1, 丨 Kehua Biotech (002022.SZ) announced that as of March 31, 2024, the total number of shares repurchased by the company through centralized bidding transactions was 8,575,800 shares, accounting for 1.67% of the company's current total share capital. The highest transaction price was 10.68 yuan/share, the minimum transaction price was 6.37 yuan/share, and the transaction amount was 69,765,653.16 yuan (excluding transaction fees).
Kehua Biotech (002022.SZ): 2023 net loss of 234 million yuan
Gelonghui, March 22丨Kehua Biotech (002022.SZ) released its 2023 annual report. In 2023, the company achieved operating income of 2,428 billion yuan, a year-on-year decrease of 65.16%; net profit attributable to shareholders of listed companies was -234 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -280 million yuan; basic earnings per share was -0.4550 yuan
Kehua Biology (002022.SZ): Has products related to HIV testing
Gelonghui March 22丨An investor asked Kehua Biotech (002022.SZ) on the investor interactive platform, “Does your company have a layout in the field of anti-AIDS drugs?” The company replied that its main business is R&D, production and sales of in vitro diagnostic reagents and medical testing instruments, and that the company has products related to HIV testing.
Kehua Biotech (002022.SZ): The UPLC Xevo TQ-S tandem mass spectrometry system is the company's agent
Gelonghui March 19 | Kehua Biotech (002022.SZ) said on the investor interactive platform that the UPLC Xevo TQ-S tandem mass spectrometry system is a product represented by the company.
Kehua Bio-Engineering Gets Nod to Register Protein Detection Kit
Shanghai Kehua Bio-Engineering (SHE:002022) received certification from the drug regulator of Shanghai to register and market a protein determination kit, the Chinese medical device maker said. The ki
Kehua Biology (002022.SZ): “Cerebrospinal Fluid/Urine Total Protein Determination Kit (Catechol Red Method)” obtained a medical device registration certificate
Gelonghui, March 4, 丨 Kehua Biotech (002022.SZ) announced that recently, Shanghai Kehua Bioengineering Co., Ltd. received the “Medical Device Registration Certificate” (in vitro diagnostic reagent) issued by the Shanghai Drug Administration. Kit for determination of total protein in cerebrospinal fluid/urine (catechol red method).
Kehua Biotech (002022.SZ): A total of 1.43% shares have been repurchased
Gelonghui, March 1, 丨 Kehua Biotech (002022.SZ) announced that as of February 29, 2024, the total number of shares repurchased by the company through centralized bidding transactions through the stock repurchase special securities account was 7,357,900 shares, accounting for 1.43% of the company's current total share capital. The highest transaction price was 10.68 yuan/share, the minimum transaction price was 6.37 yuan/share, and the transaction amount was 60.363 million yuan (excluding transaction fees).
Kehua Biology (002022.SZ): The subsidiary focuses on R&D, production and sales of microfluidic POCT instruments and reagents
Gelonghui, Feb. 29丨Kehua Biotech (002022.SZ) said on the investor interactive platform that the company's subsidiary Focus Diagnostics focuses on R&D, production and sales of microfluidic POCT instruments and reagents.
Shanghai Kehua Bio-Engineering Gets Approval for Leucine Aminopeptidase Kit
Shanghai Kehua Bio-Engineering (SHE:002022) received the medical device registration certificate for the leucine aminopeptidase test determination kit. The certificate was from the Food and Drug Admin
Kehua Biotech (002022.SZ) products obtained medical device registration certificate
Kehua Biotech (002022.SZ) announced that the company received the “Medical Device Note...” issued by the Shanghai Drug Administration
Kehua Biotech (002022.SZ): Has repurchased 1.07% of shares cumulatively
Gelonghui, Feb. 5, 丨 Kehua Biotech (002022.SZ) announced that as of February 5, 2024, the total number of shares repurchased by the company through centralized bidding transactions was 5,495,400 shares, accounting for 1.07% of the company's current total share capital. The highest transaction price was 10.68 yuan/share, the lowest transaction price was 6.42 yuan/share, and the transaction amount was 47,045,133 yuan (not including transaction fees).
Kehua Biotech (002022.SZ) released performance forecast
According to the Zhitong Finance App, Kehua Biotech (002022.SZ) released a performance forecast. Net profit to the mother in 2023 is expected to lose, mainly due to a sharp drop in market demand for related products. Facing changes in domestic and foreign markets, in order to promote the company's sustainable and healthy development, the company has accumulated momentum and increased investment in the following areas: (1) Actively adjust the product strategy layout and continue to invest in new tracks and product upgrades and iterations: innovate and compete in the fields of human medicine, animals, and automation to develop new products; maintain integrity and innovation in various areas such as infectious diseases, tumors, genetic metabolism, drug genes, blood screening, etc., and continue to promote product upgrades and iterations.
Kehua Biotech (002022.SZ) issued an advance loss. It is expected to have a net loss of 175 million yuan to 245 million yuan in 2023, changing from profit to loss over the previous year
Kehua Biotech (002022.SZ) released its 2023 annual results forecast. Net income attributable to shareholders of listed companies is expected...
Investors Don't See Light At End Of Shanghai Kehua Bio-Engineering Co.,Ltd's (SZSE:002022) Tunnel And Push Stock Down 26%
Shanghai Kehua Bio-Engineering Co.,Ltd (SZSE:002022) shares have had a horrible month, losing 26% after a relatively good period beforehand. Instead of being rewarded, shareholders who have already
Analysis
Price Target
No Data
